Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Autor: Tandler, Claudia, Heitmann, Jonas S., Michel, Tanja M., Marconato, Maddalena, Jaeger, Simon U., Tegeler, Christian M., Denk, Monika, Richter, Marion, Oezbek, Melek Tutku, Maringer, Yacine, Schroeder, Sarah M., Schneiderhan-Marra, Nicole, Wiesmüller, Karl-Heinz, Bitzer, Michael, Ruetalo, Natalia, Schindler, Michael, Meisner, Christoph, Fischer, Imma, Rammensee, Hans-Georg, Salih, Helmut R., Walz, Juliane S.

Publikováno v: In International Journal of Infectious Diseases February 2024 139:69-77

Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis.

Autor: Önder CE; Research Institute for Women's Health, University of Tübingen, 72076 Tübingen, Germany., Moustafa-Oglou M; Department of Pediatric Oncology and Hematology, University Hospital Tübingen, 72076 Tübingen, Germany., Schröder SM; Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89081 Ulm, Germany.; Department of Peptide-Based Immunotherapy, University and University Hospital Tübingen, 72076 Tübingen, Germany., Hartkopf AD; Department of Women's Health, University of Tübingen, 72076 Tübingen, Germany., Koch A; Research Institute for Women's Health, University of Tübingen, 72076 Tübingen, Germany.; Department of Women's Health, University of Tübingen, 72076 Tübingen, Germany., Seitz CM; Department of Pediatric Oncology and Hematology, University Hospital Tübingen, 72076 Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, 72076 Tübingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tübingen, a Partnership between German Cancer Research Center (DKFZ) and University Hospital Tübingen, 81675 Munich, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2023 Dec 29; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 29.